ID   WT145
AC   CVCL_A2HM
DR   Wikidata; Q105511778
RX   PubMed=12644300;
RX   PubMed=23681781;
RX   PubMed=24239860;
CC   Doubling time: 15.8 hours (Note=Non-treated), 45.9 hours (Note=1,25D3 treated) (PubMed=12644300).
CC   Transformant: ChEBI; CHEBI_254496; 7,12-dimethyltetraphene (DMBA; dimethylbenzanthracene).
CC   Derived from site: In situ; Mammary gland; UBERON=UBERON_0001911.
CC   Breed/subspecies: C57BL/6J.
DI   NCIt; C21678; Malignant neoplasms of the mouse mammary gland
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
SX   Female
AG   6-8M
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 19-12-24; Version: 6
//
RX   PubMed=12644300; DOI=10.1016/S0303-7207(02)00416-1;
RA   Zinser G.M., McEleney K., Welsh J.;
RT   "Characterization of mammary tumor cell lines from wild type and
RT   vitamin D3 receptor knockout mice.";
RL   Mol. Cell. Endocrinol. 200:67-80(2003).
//
RX   PubMed=23681781; DOI=10.1002/mc.21975; PMCID=PMC6743320;
RA   Keith M.E., LaPorta E., Welsh J.;
RT   "Stable expression of human VDR in murine VDR-null cells recapitulates
RT   vitamin D mediated anti-cancer signaling.";
RL   Mol. Carcinog. 53:286-299(2014).
//
RX   PubMed=24239860; DOI=10.1016/j.jsbmb.2013.10.022; PMCID=PMC4021002;
RA   LaPorta E., Welsh J.;
RT   "Modeling vitamin D actions in triple negative/basal-like breast
RT   cancer.";
RL   J. Steroid Biochem. Mol. Biol. 144:65-73(2014).
//